In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on SAGE Therapeutics (SAGE), with a price target of $50.00. The company’s shares closed last Friday at $39.20, close to its 52-week low of $25.02.
According to TipRanks.com, Olson is ranked 0 out of 5 stars with an average return of -9.4% and a 37.8% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.
SAGE Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $62.67, representing a 62.8% upside. In a report issued on April 28, RBC Capital also maintained a Buy rating on the stock with a $71.00 price target.
See today’s analyst top recommended stocks >>
Based on SAGE Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.96 million and GAAP net loss of $169 million. In comparison, last year the company earned revenue of $273K and had a GAAP net loss of $158 million.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAGE in relation to earlier this year. Earlier this month, Kimi Iguchi, the CFO & Treasurer of SAGE bought 4,000 shares for a total of $5,440.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Read More on SAGE: